Exscientia plc (NASDAQ:EXAI - Get Free Report)'s stock price gapped up prior to trading on Friday . The stock had previously closed at $5.66, but opened at $5.93. Exscientia shares last traded at $5.72, with a volume of 100,893 shares traded.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on EXAI. Barclays restated an "equal weight" rating and set a $5.00 price target on shares of Exscientia in a report on Tuesday, August 13th. TD Cowen reissued a "hold" rating on shares of Exscientia in a research report on Friday, August 9th.
View Our Latest Research Report on EXAI
Exscientia Stock Down 1.8 %
The firm has a 50-day moving average price of $5.32 and a two-hundred day moving average price of $5.38. The firm has a market cap of $672.13 million, a price-to-earnings ratio of -4.25 and a beta of 0.85. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.30 and a current ratio of 6.30.
Exscientia (NASDAQ:EXAI - Get Free Report) last released its quarterly earnings data on Thursday, August 15th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.05). Exscientia had a negative return on equity of 34.59% and a negative net margin of 666.80%. The company had revenue of $5.60 million for the quarter. On average, sell-side analysts forecast that Exscientia plc will post -1.12 earnings per share for the current year.
Hedge Funds Weigh In On Exscientia
Several large investors have recently bought and sold shares of the stock. GAMMA Investing LLC increased its position in shares of Exscientia by 112.1% during the first quarter. GAMMA Investing LLC now owns 4,356 shares of the company's stock worth $25,000 after purchasing an additional 2,302 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Exscientia by 76.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,274 shares of the company's stock valued at $53,000 after purchasing an additional 4,029 shares during the period. EntryPoint Capital LLC raised its stake in shares of Exscientia by 22.8% during the first quarter. EntryPoint Capital LLC now owns 31,171 shares of the company's stock worth $178,000 after purchasing an additional 5,784 shares during the last quarter. Walled Lake Planning & Wealth Management LLC acquired a new stake in shares of Exscientia during the fourth quarter worth $64,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in Exscientia in the 2nd quarter valued at $54,000. Institutional investors and hedge funds own 41.58% of the company's stock.
Exscientia Company Profile
(
Get Free Report)
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.
See Also
Before you consider Exscientia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exscientia wasn't on the list.
While Exscientia currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
